GSTM1 and chronic myelogenous leukemia, BCR-ABL1 positive: Hence, null GSTM1 seemed to be frequent in nilotinib responders with possible influence on drug response..This is contrary to previous study where the GSTM1 null allele was associated with treatment failure in imatinib treated CML patients [29].